Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug, Oubakain Hydrochloride Eye Drops, which is intended for surface anesthesia in ophthalmology [1] Company Summary - The approved product is a single-dose formulation that does not contain preservatives [1] - The active ingredient in the eye drops is Oubakain Hydrochloride [1] - This approval marks a significant milestone for the company in expanding its product offerings in the ophthalmic field [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-058 沈阳兴齐眼药股份有限公司 药品通用名称：盐酸奥布卡因滴眼液 英文名/拉丁名：Oxybuprocaine Hydrochloride Eye Drops 剂型：眼用制剂 规格：0.4%（0.5ml：2mg） 注册分类：化学药品 4 类 药品注册标准编号：YBH28692025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 今日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的盐酸奥布卡因滴眼液《药品注册 证书》。现将有关事宜公告如下： 一、药品基本情况 二、药品的其他相关情况 本品是以盐酸奥布卡因为活性成份的滴眼液，公司本次获批的盐酸奥布卡因 滴眼液为不含抑菌剂单剂量产品，适应症为眼科领域内的表面麻醉。原研药品已 进口中国。截至目前，国内已有同品种仿制药获批上市。 1 三、风险提示 上市 ...

Core Viewpoint - The company emphasizes that its stock price is influenced by various factors, including market environment, industry trends, investor preferences, and expectations [1] Group 1: Company Strategy - The management is committed to improving operational performance through steady operations and fulfilling information disclosure obligations [1] - The company actively communicates its investment value to the market and aims to provide stable and long-term value returns to shareholders [1] Group 2: Investor Relations - The company focuses on enhancing investor communication and has a strategy of continuous and stable cash dividends to reward investors [1] - Future efforts will include optimizing management practices and improving governance structures to ensure consistent value returns for shareholders [1]

Investment Rating - The report indicates a positive investment outlook for the dry eye disease treatment drug industry, with a projected compound annual growth rate (CAGR) of 10% from 2025 to 2030, and the market size expected to exceed 9.6 billion yuan by 2030 [4][31]. Core Insights - The dry eye disease treatment market in China is characterized by a dual-track competition between foreign and domestic companies, with local firms like Xingqi Eye Medicine and Hengrui Medicine gradually breaking the monopoly of foreign enterprises through independent research and development and collaborative efforts [4][10]. - The number of dry eye disease patients in China has surpassed 360 million, with an annual growth rate of 10%, indicating a continuous expansion of diagnosis and treatment demand [4][11]. - The market is shifting from reliance on traditional treatments like artificial tears to innovative therapies, including immunosuppressants and new drug delivery systems, marking a transition to a more precise and individualized treatment approach [4][17][34]. Summary by Sections Industry Definition - Dry eye disease (DED) is caused by insufficient tear production or instability of the tear film, leading to various ocular discomforts. Treatment is individualized and can include drug therapy, physical therapy, and surgical options [5]. Drug Classification - Dry eye treatment drugs can be categorized based on their mechanisms of action, including lubricating and repairing agents, anti-inflammatory drugs, and antibacterial agents [6][7][8]. Industry Characteristics - The increase in screen time among residents has led to a rise in dry eye disease cases, creating significant market potential. The market is currently dominated by artificial tears and cyclosporine eye drops [10][12]. Market Size and Growth - The market size for dry eye treatment drugs is projected to grow from 12.755 billion yuan in 2025 to 19.306 billion yuan by 2030, with a CAGR of 8.64% [31][34]. Competitive Landscape - The high-end market for dry eye treatment drugs is primarily dominated by foreign brands, but domestic companies are making significant strides through innovation and competitive pricing [41][42][43]. Policy Analysis - Recent policies aim to enhance eye health services and promote awareness of dry eye disease, which is expected to further stimulate market growth [39][40]. Industry Chain Analysis - The industry chain includes upstream raw material suppliers, midstream drug manufacturers, and downstream sales channels, with a focus on innovation and quality improvement to enhance competitiveness [18][19][20].

Core Viewpoint - The upgrade from "Quality Month" to "Quality Season" at Shenyang Xingqi Eye Pharmaceutical Co., Ltd. signifies a comprehensive enhancement in quality management practices, leading to more extensive participation and deeper engagement across the organization [1][2]. Group 1: Activity Structure and Content - The "Quality Season" initiative includes a systematic upgrade in content structure, featuring four core dimensions: quality culture shaping, quality capability enhancement, quality innovation practice, and quality results promotion, with a total of 16 sub-activities planned [1][2]. - New targeted modules have been introduced, such as "Senior Leaders Discuss Culture" to convey the core quality culture from a strategic perspective, and "Quality Management Model Presentation" to optimize quality management methods [2][3]. Group 2: Implementation and Depth - The transition to "Quality Season" was initiated after the previous "Quality Month," with August designated as a planning month to ensure thorough preparation and effective execution of activities [3]. - The activities were designed to extend across various operational units, ensuring that quality awareness and methods are integrated into all aspects of the company's operations, moving from a broad approach to a deeply rooted one [3][4]. Group 3: Participation and Engagement - The "Quality Season" activities emphasized full participation and coverage, with most activities open to all departments, fostering a culture of quality across the organization [5][6]. - Activities such as the Quality Lecture Hall and knowledge competitions were aimed at enhancing employees' understanding of quality standards and regulations, while practical skill competitions provided a platform for hands-on learning [5][6]. Group 4: Recognition and Impact - The company recognized exemplary employees through awards like "Most Beautiful Quality Person" and "EHS Star," aiming to inspire a collective commitment to quality improvement across the organization [6].

Group 1 - The core point of the article is that Xingqi Eye Pharmaceutical (SZ 300573) held its 13th meeting of the 5th board of directors on November 17, 2025, to review the report on the use of previously raised funds [1] - For the first half of 2025, the company's revenue composition was 96.15% from pharmaceutical manufacturing and 3.85% from other businesses [1] - As of the report date, Xingqi Eye Pharmaceutical has a market capitalization of 17.8 billion yuan [1]

沈阳兴齐眼药股份有限公司 截至 2025 年 9 月 30 日止 前次募集资金使用情况报告及鉴证报告 目 录 页 次 | 一、 | 前次募集资金使用情况报告的鉴证报告 | 1-2 | | --- | --- | --- | | 二、 | 前次募集资金使用情况报告 | 1-7 | 关于沈阳兴齐眼药股份有限公司 截至2025年9月30日止 前次募集资金使用情况报告的鉴证报告 信会师报字[2025]第ZA15165号 沈阳兴齐眼药股份有限公司全体股东： 我们接受委托，对后附的沈阳兴齐眼药股份有限公司（以下简称 "兴齐眼药"）截至2025年9月30日止前次募集资金使用情况报告（以 下简称"前次募集资金使用情况报告"）执行了合理保证的鉴证业务。 一、管理层的责任 兴齐眼药管理层的责任是按照中国证券监督管理委员会《监管规 则适用指引——发行类第7号》的相关规定编制前次募集资金使用情 况报告。这种责任包括设计、执行和维护与前次募集资金使用情况报 告编制相关的内部控制，确保前次募集资金使用情况报告真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏。 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史 财务信息 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-057 沈阳兴齐眼药股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长刘继东先生召集，会议通知于 2025 年 11 月 14 日通 过电子邮件等形式送达至各位董事，董事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 11 月 17 日在公司会议室以现场与通讯会议相结合 的方式召开。 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长刘继东先生主持，公司高级管理人员列席了本次董 事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 根据相关法律、法规和规范性文件的规定，公司对截至 2025 年 9 月 30 日的 前次募集资金使用情况编制了《沈阳兴齐眼药股份有限公司前次募集资金使用情 况报告》；立信会计师事务所（特殊普通合伙）对《沈阳兴 ...

沈阳兴齐眼药股份有限公司 截至 2025 年 9 月 30 日止 前次募集资金使用情况报告 沈阳兴齐眼药股份有限公司 截至2025年9月30日止 前次募集资金使用情况报告 根据中国证券监督管理委员会《监管规则适用指引——发行类第7号》的相关规定，本公司将 截至2025年9月30日止前次募集资金使用情况报告如下： 一、 前次募集资金基本情况 前次募集资金的数额、资金到账时间 经中国证券监督管理委员会证监许可[2021]1343 号文批准，公司向特定对象发行人 民币普通股 5,763,282 股，募集资金总额为人民币 599,669,492.10 元，实际收到募集 资金为人民币 581,870,425.73 元（已扣除承销费用（含增值税））。上述募集资金于 2021 年 12 月 22 日全部到位，相应实收情况已经立信会计师事务所（特殊普通合伙） 审验，并出具信会师报字[2021]第 ZA15987 号验资报告。 截至 2025 年 9 月 30 日止，前次募集资金在银行募集资金专户的存储情况如下： 单位：人民币元 | 开户银行 | 账号 | 初始存放金额 | 截止日余额 | 备注 | | --- | --- | ...

目 录 页 次 | 一、 | 非经常性损益明细表鉴证报告 | 1-2 | | --- | --- | --- | | 二、 | 非经常性损益明细表 | 1-3 | 2022 年度、2023 年度、2024 年度及 截至 2025 年 9 月 30 日止 9 个月期间 非经常性损益明细表及鉴证报告 非经常性损益明细表鉴证报告 沈阳兴齐眼药股份有限公司 信会师报字[2025]第 ZA15155 号 沈阳兴齐眼药股份有限公司全体股东： 我们接受委托，对后附的沈阳兴齐眼药股份有限公司（以下简称 "贵公司"）2022 年度、2023 年度、2024 年度及截至 2025 年 9 月 30 日止 9 个月期间的非经常性损益明细表（以下简称"非经常性损 益明细表"）执行了合理保证的鉴证业务。 一、管理层对非经常性损益明细表的责任 贵公司管理层负责按照中国证券监督管理委员会颁布的《公开发 行证券的公司信息披露解释性公告第 1 号——非经常性损益（2008 年修订）》的相关规定编制 2022 年度非经常性损益明细表，按照中 国证券监督管理委员会颁布的《公开发行证券的公司信息披露解释性 公告第 1 号——非经常性损益（2023 ...